We have reported previously the novel δ-opioid agonist, SN-28, which was more potent in in vitro assays than the prototype δ-agonists, TAN-67 and SNC-80. However, when administered by subcutaneous injection, this compound showed no analgesic effect at dosages greater than 30mg/kg in the acetic acid writhing test. We speculated that SN-28 was not effective in the test because the presence of the charged ammonium groups prevented its penetration through the blood-brain barrier. On the basis of our proposal, we designed the novel δ-agonist, KNT-127, which was effective with systemic administration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2010.08.083 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!